
Tyra Biosciences downgraded to Hold ahead of key phase 2 trial data for FGFR3-targeting drug.
Tyra Biosciences has been downgraded to a Hold rating as it approaches critical phase 2 trial results for its drug dabogratinib, targeting FGFR3-altered IR-NMIBC patients. The company faces significant near-term risks and opportunities from multiple ...



